HER2-positive (+) breast cancers, defined by HER2 overexpression and/or amplification, are often addicted to HER2 to maintain their malignant phenotype. Yet, some HER2+ tumors do not benefit from anti-HER2 therapy. We hypothesize that HER2 amplification levels and PI3K pathway activation are key determinants of response to HER2-targeted treatments without chemotherapy.
A combinatorial biomarker predicts pathologic complete response to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2+ breast cancer / De Angelis, C.; Veeraraghavan, J.; Mao, R.; Wang, T.; Herrera, S.; Pavlick, A. C.; Contreras, A.; Nuciforo, P.; Mayer, I. A.; Forero, A.; Nanda, R.; Goetz, M. P.; Chang, J. C.; Wolff, A. C.; Krop, I. E.; Fuqua, S. A. W.; Prat, A.; Hilsenbeck, S. G.; Weigelt, B.; Reis-Filho, J. S.; Gutierrez, C.; Osborne, C. K.; Rimawi, M. F.; Schiff, R.. - In: ANNALS OF ONCOLOGY. - ISSN 0923-7534. - 30:6(2019), pp. 927-933. [10.1093/annonc/mdz076]
A combinatorial biomarker predicts pathologic complete response to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2+ breast cancer
De Angelis C.Co-primo
;
2019
Abstract
HER2-positive (+) breast cancers, defined by HER2 overexpression and/or amplification, are often addicted to HER2 to maintain their malignant phenotype. Yet, some HER2+ tumors do not benefit from anti-HER2 therapy. We hypothesize that HER2 amplification levels and PI3K pathway activation are key determinants of response to HER2-targeted treatments without chemotherapy.| File | Dimensione | Formato | |
|---|---|---|---|
|
1-s2.0-S0923753419311949-main.pdf
accesso aperto
Tipologia:
Versione Editoriale (PDF)
Licenza:
Dominio pubblico
Dimensione
201.16 kB
Formato
Adobe PDF
|
201.16 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
